Notice from Pharmac:
Thursday 12 September 2024

Subject: Pharmac asking for feedback on a proposal to fund lisdexamfetamine and remove the renewal criteria for stimulant treatments

Kia ora

Pharmac is now consulting publicly on a proposal to fund lisdexamfetamine for the treatment of ADHD and to remove the renewal criteria for stimulant treatments - methylphenidate, dexamfetamine and modafinil.

I know this will be of interest to you and your networks, and I invite you to share this information so that as many people as possible are able to provide feedback. The feedback we receive is very important for the funding proposal we will take to Pharmac’s Board for a decision.

Consultation on the funding proposal for lisdexamfetamine opens on Thursday 12 September and closes on Thursday 26 September 2024. Consultation on the removal of the renewal criteria opens on Thursday 12 September and closes on Thursday 3 October 2024.


More information about Pharmac’s proposal, including how to provide feedback, is at:

• Proposal to fund lisdexamfetamine for the treatment of ADHD
• Proposal to remove the renewal criteria for stimulant treatments

 
These proposals were developed following advice from clinicians and people living with ADHD. Pharmac is committed to funding medicines that help people live good, healthy lives with their whānau and communities.
​
After we have considered the feedback received in the public consultation, the funding proposal will go to Pharmac’s Board, or a delegate, for a decision. If approved, we expect that lisdexamfetamine will be available, and the renewal criteria will be removed, from 1 December 2024.


We will keep Pharmac’s website updated as the proposal progresses but let me know if you have any questions.


Ngā mihi,